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ABSTRACT 
The epidermal growth factor receptor (EGFR) belongs to the well-studied ErbB family of 
receptor tyrosine kinases. EGFR is activated by numerous endogenous ligands that promote 
cellular growth, proliferation and tissue regeneration. In the present study, we demonstrate 
a novel function for EGFR and its natural ligand, epiregulin (EREG), in pain processing. We 
show that inhibition of EGFR with clinically used compounds strongly reduces nocifensive 
behavior in mouse models of inflammatory and chronic pain. EREG enhances nociception 
through a mechanism that involves the PI3K/AKT/mTOR pathway and matrix 
metalloproteinase-9. In sensory neurons, EREG potentiates the calcium influx induced by 
the TRPV1 agonist, capsaicin, but not the TRPA1 agonist, mustard oil. Both the EGFR and 
EREG genes display genetic association with the development of chronic pain in several 
clinical cohorts of temporomandibular disorder. Thus, EGFR and EREG may be suitable 
therapeutic targets for persistent pain conditions.  
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INTRODUCTION  
Chronic pain is a major human health problem affecting almost one-quarter of the population at 
any one time (1-3). Chronic pain is difficult to manage and treatment options are limited and 
associated with unwanted side effects, and the identification of novel pharmacotherapeutic targets 
remains challenging. Recently, the epidermal growth factor receptor (EGFR) has received 
attention for its therapeutic potential. EGFR inhibition is the first-line treatment for non-small cell 
lung cancer, and there have been a number of case reports suggesting that EGFR inhibition 
provides rapid relief of cancer pain (4-8). Cancer patients administered EGFR inhibitors report a 
significant reduction in pain scores and an overall improvement in quality of life without an 
obvious effect on tumor progression and size (6).  
 EGFR is a member of the ErbB family of tyrosine kinase receptors (9) that regulate cellular 
growth, survival, proliferation and differentiation of fibroblasts and hepatocytes (10, 11). Several 
ligands can bind to and activate EGFR, including EGF, transforming growth factor α (TGF- α), 
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, betacellulin, and epiregulin 
(EREG) (9). The downstream effects of EGFR are mediated by a number of important signaling 
pathways, including mitogen-activated protein kinase (MAPK) (8) and PI3K/AKT/mammalian 
target of rapamycin (mTOR)—which are known to regulate pain (12-14). EGFR has been shown 
to affect receptors important for pain processing, including opioid receptors (15), β-adrenergic 
receptors (16) and cannabinoid type 1 (CB1) and transient receptor potential cation channel, 
subfamily V, member 1 (TRPV1) receptors (17). However, none of these previous reports 
examined these interactions using behavioral or cellular models specifically relevant to pain 
processing. Here, our primary goal was to understand the EGFR pathway’s role and mechanism 
of action in pain processing.  
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 We investigated the role of the EGFR and its ligands in nociception using murine behavioral 
and ex vivo studies to identify mechanistic targets for EGFR signaling in pain that may be 
generalizable across pain conditions. Specifically, we demonstrate herein that inhibition of the 
tyrosine kinase site of the EGFR, using both experimental and clinically available compounds, is 
analgesic against a variety of tonic and chronic pain modalities in the mouse. The genes coding 
for both EGFR and EREG demonstrate genetic association with a human chronic pain syndrome, 
temporomandibular disorder, and genetic inhibition of EGFR modulates pain behavior in both 
mice and Drosophila. Finally, we show that stimulation of EGFR, by its ligand EREG specifically, 
activates DRG neurons, producing pain behaviors through a mechanism that involves TRPV1, the 
PI3K/AKT/mTOR/4E-BP1 signaling pathway, and matrix metalloprotease-9 (MMP-9), a 
molecule known to be involved in inflammation and the early stages of chronic pain (18). 
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RESULTS 
 
Modulation of EGFR affects pain sensitivity in mice 
To assess the effect of EGFR inhibition on pain in mice we tested one preclinical (tyrphostin AG 
1478; hereinafter, AG 1478; 10 mg/kg) and two clinically available (50 mg/kg gefitinib and 75 
mg/kg lapatinib) EGFR tyrosine kinase inhibitors in a battery of algesiometric assays. Doses were 
chosen based on prior in vivo efficacy against stress-induced necrotic lesions in the heart (AG 
1478), and chemoprevention of lung cancer (gefitinib) or breast cancer (lapatinib) in mice (19-21). 
We first confirmed that none of the drugs, delivered systemically and at very high doses (AG 1478, 
100 mg/kg; gefitinib, 300 mg/kg; lapatinib, 300 mg/kg) produced significant ataxia over a 1-h 
testing period on the rotarod test (Figure 1A). These drugs did not affect acute noxious thermal 
(Figure 1B) or mechanical (Figure 1C) sensitivity. By contrast, in the formalin test EGFR 
inhibitors produced robust inhibition of tonic inflammatory pain (Figure 1D), without affecting 
edema (not shown). Compilation of full dose-response curves revealed dose-dependent analgesia 
only in the late or tonic phase (Figure 1E), with efficacy and potencies comparable to morphine 
(see Supplemental Table 1). Further, EGFR inhibition completely reversed the thermal 
hypersensitivity produced by an inflammatory mediator, -carrageenan, at 20-40 min 
post-injection (Figure 1F). Finally, we examined mechanical hypersensitivity (allodynia) after 
longer-lasting inflammatory and neuropathic injuries. Higher doses were required, but all drugs 
produced complete and dose-dependent reversal of allodynia in complete Freund’s adjuvant (CFA) 
model of inflammatory pain (Figure 1G). Similarly, all drugs produced complete and 
dose-dependent reversal of allodynia in the spared nerve injury (SNI) model of neuropathic pain 
(Figure 1H). Half-maximal analgesic doses and confidence intervals for the EGFR inhibitors for 
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CFA and SNI are presented in Supplemental Table 2. In a separate experiment we used the chronic 
constriction nerve injury (CCI) model of chronic pain to provide generalizability across 
neuropathic assays. Similar to SNI, EGFR inhibition produced robust anti-allodynia on CCI 
(Figure 1I).  
  
Activation of EGFR by EREG, but not other EGFR ligands, promotes nociception 
In order to determine whether EGFR activation is sufficient to increase nociception, we screened 
a number of EGFR ligands for their ability to promote nocifensive behaviors in the formalin test. 
We find that late phase formalin-induced nocifensive behaviors were enhanced in a dose-
dependent manner with intrathecal (i.t.) injections of EREG, but none of the other tested EGFR 
ligands including betacellulin, TGF-, amphiregulin or epidermal growth factor (EGF) (Figure 
2A). EREG produced a robust and dose-dependent increase in licking behavior that was 
indistinguishable from that produced by nerve growth factor (NGF), known for its prominent role 
in pain processing (Figure 2A). Next, we assessed whether EREG enhanced pain behaviors 
induced by capsaicin or mustard oil, two potent algogens known to activate TRPV1 and TRPA1, 
respectively. Intrathecal delivery of EREG potentiated nocifensive behavior from intraplantar 
capsaicin but not mustard oil (Figure 2B). In addition, the TRPV1 antagonist, AMG 9810 (30 
mg/kg; i.p.), but not the TRPA1 antagonist, HC-030031 (30 mg/kg; i.p.) blocked the hyperalgesic 
effect of EREG on the late phase of the formalin test (Figure 2C). Spinal delivery of EREG 
produced both thermal (Figure 2D) and mechanical (Figure 2E) pain hypersensitivity in the 
absence of injury. EREG’s hyperalgesic effects on the formalin test were independent from other 
tyrosine receptor kinases, as K252a (an inhibitor of TrkA, TrkB and TrkC) but not EGFR failed to 
block EREG-induced hypersensitivity (Supplemental Figure 1). Furthermore, administration of 
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AG 1478 blocked the hyperalgesic effects of EREG on the formalin test, but did not reverse the 
hyperalgesia produced by intrathecal injections of NGF, a potent activator of TrkA, confirming 
that EREG-mediated hypersensitivity is dependent on the EGFR and not TrkA (Supplemental 
Figure 1).  
  
EGFR gene mutant effects in mice and Drosophila 
In order to confirm the efficacy of EREG in promoting pain hypersensitivity, we tested a partial 
loss of function EGFR mutant mouse for EREG-induced hypersensitivity. The EGFRvIII/EGFR 
mutant mouse has a large deletion of the extracellular domain that renders EGFR constitutively 
active but with no ability to bind extracellular ligands (22). The homozygous mutation is 
embryonically lethal, and thus we tested EGFR heterozygotes for EREG-induced pain sensitivity 
on the formalin test. Basal formalin-induced licking behavior of EGFR heterozygotes was 
increased, but EREG no longer produced hypersensitivity on the formalin test (Figure 2F). The 
increased formalin sensitivity ofEGFR heterozygotes was likely due to constitutive activity of 
the EGFR. Since further activation by ligand binding is reduced in this mutant, EREG would not 
be expected to increase pain behavior any further.  In addition, we used genetic knockdown and 
somatic Drosophila mutants to confirm that EGFR acts via sensory neurons to mediate nociception 
in response to a 46 °C probe (Supplemental Figure 2). The Drosophila data establish that the EGFR 
system is a conserved component of the nociceptive processing apparatus. 
 EGFR is conserved from humans through to the fruit fly Drosophila melanogaster (23). Since 
fruit fly larvae exhibit robust nociceptive behavior in response to noxious heat (24), we next tested 
if EGFR also regulates nociception in insects. Animals with Egfr knocked down in peripheral ppk+ 
nociceptor neurons exhibit impaired thermal nociception (Supplemental Figure 2, A–C), and 
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conversely reintroduction of intact Egfr specifically in ppk+ sensory neurons was sufficient to 
rescue nociception in whole body Egfr somatic mutant animals (Supplemental Figure 2, D–F). 
Together, these data establish that the EGFR system is a conserved component of the nociception 
apparatus, regulating peripheral nociceptor function in vivo. 
 
EREG and EGFR genetic loci are associated with the risk of development of a chronic pain 
condition 
Since our studies in mice indicate a robust role for EREG and EGFR in mediating pain, we next 
searched for evidence that EGFR contributes to pain in a human clinical population. Three human 
cohorts of a common chronic pain condition, temporomandibular disorder (TMD), were assessed 
in four case-control association analyses (Supplementary Table 3) on a panel of 358 pain-relevant 
candidate genes. In the first analysis, designed to minimize experimental variance, we contrasted 
127 Caucasian female TMD cases from the OPPERA (Orofacial Pain: Prospective Evaluation and 
Risk Assessment) (25) cohort against a subset of 231 demographically matched “super-controls,” 
who reported absolutely no procedural pain at exam. Of the genes screened, EREG (rs1563826, 
odds ratio = 0.4, p=2.0 x 10-4) (Figure 3A), and EGFR (rs1140475, odds ratio = 2.6, p=2.2 x 10-4) 
(Figure 3B) demonstrated the highest association with the development of TMD. In addition, the 
majority of SNPs deviating from the QQ plot were located in either EREG or EGFR loci 
(Supplemental Figure 3A). Formal pathway analysis identified the EGFR signaling pathway as 
significantly associated with TMD (p=0.0013; Supplemental Table 4). Nominally significant 
(p<0.05) associations were also observed for EREG and EGFR in the full OPPERA cohort, in 
which TMD cases were contrasted with all 731 enrolled TMD-free controls (Figure 3, A and B). 
We replicated these association results in two independent cohorts of Caucasian females, including 
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one case-control study of 200 TMD cases and 198 controls (“TMD case-control cohort”) (26), and 
another prospective study of 186 initially pain-free subjects in which 15 developed TMD over a 
three-year follow-up period (“pre-OPPERA cohort”) (27). These analyses identified several 
additional single nucleotide polymorphisms (SNPs) with either significant or borderline 
associations (Figure 3, A and B). Whereas the pattern of association within the EREG gene locus 
was identical in all four cohorts (Figure 3A), with SNP rs1563826 showing the strongest 
association with TMD, the pattern of association for EGFR differed between cohorts (Figure 3B). 
To explain the discrepancies in single SNP results between cohorts, the EGFR gene locus was 
subjected to haplotype analysis that produced convergent results (Supplemental Table 5). 
 Total RNA isolated from blood leukocytes was collected from participants of the TMD 
case-control study. Relatively high expression levels of EREG (but not EGFR) in leukocytes 
allowed us to measure EREG mRNA using quantitative PCR (qPCR) in all subjects, and evaluate 
its association with EREG genotypes. The minor allele T of SNP rs1563826, which showed the 
strongest association with decreased odds of TMD (Figure 3C), was also associated with lower 
EREG mRNA levels (Figure 3D), suggesting that higher levels of EREG contributes to 
hyperalgesic states in patients.  
 We then assessed the EREG gene locus for functional SNPs potentially responsible for 
transcript regulation. No SNPs with minor allele frequency >5% are reported within 5 kB upstream 
of the EREG promoter. However, the synonymous rs2367707 SNP within the EREG coding region 
was found to be in close-to-perfect linkage disequilibrium with rs1563826, and with an almost 
identical p-value of TMD risk (Figure 3A). To examine the effect of rs2367707 allelic variants on 
transcript levels, we transfected HEK293 cells with expression constructs that carried allelic 
variants of rs2367707. In line with the genetic effect of the EREG haplotype on endogenous mRNA 
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levels, the minor A allelic variant of EREG showed significantly lower transcript stability than the 
major G allelic variant (Figure 3E). The association of EGFR and EREG with chronic pain in a 
clinical cohort is a significant translational complement to our mouse data, and supports the 
potential value of targeting EGFR for chronic non-cancer pain management in humans.  
 
EREG levels and EGFR phosphorylation are upregulated in mouse models of chronic pain 
The finding of increased EREG mRNA levels in leukocytes of TMD patients (Figure 3D) 
prompted us to investigate whether chronic pain states in mice are associated with increased levels 
of EREG in the blood. CFA and SNI (but not formalin) produced a massive upregulation of EREG, 
as assessed by ELISA (Figure 4A). To study the site of EREG action we investigated the 
distribution of EGFR in DRGs and spinal cord. EGFR was non-homogeneously expressed by all 
DRG neurons within the cytoplasm of individual DRG cells, and neuronal size did not affect EGFR 
expression levels (Figure 4, B and C). In the spinal cord, EGFR expression was very low and was not 
found on neurons (Supplemental Figure 4). Immunostaining of EREG was not possible due to lack of 
appropriate antibodies. Based on our findings of increased EREG levels in CFA and SNI, we 
hypothesized that the activity of the EGFR should be increased in these conditions. To this end, 
we measured the phosphorylation of EGFR (on Tyr1068), which is reflective of EGFR activation, 
in lysates prepared from mouse DRG. EGFR phosphorylation was significantly increased 
following CFA and SNI (Figure 4, D and E), consistent with the hypothesis that chronic 
inflammatory and neuropathic injury-induced increases in EREG levels enhances EGFR 
phosphorylation. Since EREG potentiated capsaicin-dependent nocifensive behavior, we next  
measured whether EREG (200 ng/ml) potentiates TRPV1-dependent calcium transients in cultured 
DRG neurons. EREG caused a robust increase of calcium responses after a single application of 
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capsaicin (1 M) but not mustard oil (100 nM), confirming at the cellular level that EREG 
potentiates TRPV1 but not TRPA1 responses (Figure 4, F and G; see also Supplemental Figure 5). 
 
EREG pain hypersensitivity is mediated by a signal transduction pathway involving mTOR, 
translational regulation, and MMP-9 
 Since our preclinical and clinical data indicated a critical role of EREG (but not other EGFR 
ligands) and EGFR in pain processing, we sought to determine the intracellular machinery by 
which EREG-mediated EGFR activation increases pain. EGFR signaling has previously been 
shown to increase the activity of mTOR (28), a master regulator of mRNA translation (29, 30). 
Therefore, we hypothesized that mTOR is a downstream effector of EGFR with respect to pain. 
We investigated the contribution of mTOR signaling to EREG-induced hypersensitivity by 
screening nocifensive behaviors on the formalin test and disrupting elements of the mTOR signal 
transduction pathway, either with pharmacological inhibitors or, where available, using null 
mutants (See Figure 5A for an overview of the pathway). Pretreatment with wortmannin, a 
covalent inhibitor of phosphoinositide 3'-kinase (PI3K), completely abolished EREG-induced 
hypersensitivity without affecting formalin-induced pain behavior per se (Figure 5B). Next, we 
tested two inhibitors of mTOR, rapamycin and CCI 779. At higher doses, these drugs produced 
analgesia on the formalin test, as has been reported previously (29, 30). However, at lower doses, 
both drugs prevented EREG-induced hypersensitivity without affecting formalin-induced pain 
behavior per se (Figure 5C). mTOR regulates mRNA translation via two downstream effectors:  
ribosomal protein S6 kinases (S6Ks) and eukaryotic translation initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1). Mutant mice lacking expression of both S6K 1 and S6K 2 
(S6K1/2 double knockout) showed completely intact EREG-induced hypersensitivity (Figure 5D), 
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whereas 4E-BP1-deficient mice displayed no EREG-induced hypersensitivity (Figure 5E). 4E-
BP1 represses the formation of the eukaryotic translation initiation factor F (eIF4F) complex, 
which is a critical regulator of cap-dependent translation. An inhibitor of eIF4F complex, 4EGI-1, 
blocked EREG-induced hypersensitivity (Figure 5F), further supporting the role of 
mTOR/4E-BP1/eIF4F in pain. To determine whether EREG hypersensitivity was mediated in part 
by ERK signaling, we used the MEK1/MEK2 inhibitor PD98059 (31). A low concentration of 
PD98059 did not block EREG-induced hypersensitivity on either the formalin test or the von Frey 
test (Supplemental Figure 6), suggesting that EREG does not potentiate pain behavior through 
enhanced ERK signaling. Since enhanced eIF4F complex formation has been shown to increase 
endogenous metalloproteinase-9 (MMP-9) in blood (32), we used tissue inhibitor of 
metalloproteinases-1 (TIMP-1), an endogenous blocker of MMP-9, and Mmp9-/- mice to study 
whether MMP-9 signaling is important for EREG-induced pain hypersensitivity. TIMP-1 
prevented (Figure 5G, also see Supplemental Figure 7A) and Mmp9-/- mice did not display 
EREG-induced hypersensitivity (Figure 5H). We further tested the importance of MMP-9 for 
EGFR pain signaling by confirming that the analgesic efficacy of gefitinib in the formalin test was 
abolished in Mmp9 -/- mice (Supplemental Figure 7B).  
 To further study the role of mTOR and MMP-9 in EGFR-mediated pain, we examined the 
phosphorylation of mTOR pathway components in DRG lysates. Formalin treatment alone did not 
significantly increase the phosphorylation of AKT (p-AKT), but EREG increased p-AKT in DRG 
tissue relative to control (Figure 6, A and B). Congruent with our behavioral data, both formalin 
and EREG increased the phosphorylation of 4E-BP1 (p-4E-BP1) in DRG tissue, and co-treatment 
with rapamycin prevented this increase (Figure 6, A and C). Further, p-S6 was significantly 
increased with EREG treatment, and again, co-treatment with rapamycin prevented the increases 
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(Figure 6, A and D). Finally, MMP-9 protein levels were increased in DRG tissue after formalin 
or EREG injection, and this increase was blocked with rapamycin inhibition of mTOR (Figure 6, 
A and E). 
 To determine whether the increase in MMP-9 protein levels following EREG treatment was 
the result of increased Mmp9 mRNA translation, DRG extracts were fractionated on sucrose 
density gradients, and the distribution of Mmp9 mRNA across these gradients was determined by 
qPCR analysis. In DRG extracts, Mmp9 mRNA shifted to the heavy polysome fractions after 
EREG injection, indicative of enhanced translation (Supplemental Figure 8). Rapamycin blocked 
this shift, indicating that in the DRG, EREG stimulates Mmp9 mRNA translation in an mTOR-
dependent manner. Taken together our results support a key role for mTOR, the eIF4F translational 
initiation complex, and MMP-9 signaling in EGFR-mediated pain behavior.  
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DISCUSSION 
  
Although there are indications from the clinical literature that EGFR inhibition may have analgesic 
properties (5, 6, 8), this possibility has not heretofore been examined systematically. Here, we used 
a broad range of techniques and data analyses to demonstrate that: 1) EGFR inhibition is analgesic 
and activation of the EGFR by EREG enhances pain; 2) EREG and EGFR display a genetic 
association with the development of chronic pain in clinical cohorts of temporomandibular 
disorder; and 3) EREG increases pain behavior and signaling through a mechanism that involves 
TRPV1 and mTOR/eIF4F/MMP-9-dependent signaling in the DRG.  
 We find that the EGFR is expressed by all DRG sensory neurons (Figure 4, B and C), and 
show that EREG potentiates capsaicin-induced calcium influx, suggesting that functional EREG 
receptors are present in DRG neurons (Figure 4F and G). In addition, we provide compelling 
evidence that EREG increases pain sensitivity through EGFRs, whereas other EGFR ligands do 
not appear to play a role. This is consistent with prior observations that EGF or the heparin-bound 
EGF do not increase sensitivity to painful stimuli (33). EGF-like growth factors, including EREG, 
stimulate a variety of biological responses, and it is thought that ligand-induced homo- and 
heterodimerization can account for the majority of this diversity (34, 35). For instance, EREG is 
known to bind to and phosphorylate heterodimers of EGFR and ErbB-4, but other EGF ligands 
(i.e. EGF and amphiregulin) only activate EGFR homodimers (36, 37). We suspect that an 
associated membrane protein, such as ErbB4 is involved in EREG-induced hypersensitivity, but 
this currently remains unclear.  
 Our human data further support a role of EREG in pain as we find that EREG was associated 
with TMD development and upregulated in the blood of the patients. Moreover, our genetic 
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association results revealed a strong effect of genetic polymorphism in the EREG–EGFR system 
distinguishing those with chronic pain from controls. The observed association between TMD risk, 
EREG mRNA level and transcript stability, suggests that rs2367707 may be the functional SNP in 
humans. The fact that the TMD protective allele is associated with lower mRNA expression is 
congruent with our rodent findings. The EGFR SNPs tested in this study are probably only markers 
of the true effect-producing variants, but both 5’- and 3’-located SNPs within the EGFR locus 
showed association signals, suggesting both expression differences and transcript stability, 
respectively, may alter TMD risk. Thus, our results suggest that targeting EGFR and EREG for 
pain therapies may be an effective strategy. Importantly, since EGFR inhibition is associated with 
adverse side effects—folliculitis, hair loss and skin rash—inhibition of EREG may constitute an 
improved therapeutic option for pain management. 
 At the cellular level, the effects of EREG on EGFR involve TRPV1, as co-application of 
capsaicin enhanced EREG-induced activation of sensory neurons, and blockade of TRPV1 
attenuated EREG hyperalgesia in the formalin assay. TRPV1 has been shown to induce EGFR 
transactivation in a model of epithelial wound healing, leading to PI3K/AKT stimulation (17). This 
is in line with our current findings that showed disruption of PI3K/AKT/mTOR signalling with 
specific inhibitors of the AKT/mTOR pathway blocked, and 4E-BP1 null mice lacked, EREG-
induced hypersensitivity. In the DRG, EREG or formalin increased the phosphorylation of both 
S6 and 4E-BP1, the two main downstream targets of mTOR. However, since S6K1/2 null mutant 
mice had intact EREG-induced hypersensitivity we conclude that S6K is not necessary for 
EREG-stimulated pain behavior. In addition, our results indicate that EREG-induced pain behavior 
is not mediated by ERK signalling, an observation that is consistent with data showing that EREG 
does not activate ERK in DRG neurons (33). Further, our data indicate that the phosphorylation of 
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4E-BP1 increases the translation of MMP-9, and pharmacological or genetic reduction of MMP-9 
activity renders EREG and EGFR antagonists ineffective against inflammatory pain. Together, our 
results indicate that EREG upregulation in the blood may activate EGFRs on DRG neurons to 
induce hypersensitivity through transactivation of TRPV1 and the mTOR signaling pathway, 
which increases MMP-9 translation. It is likely that EREG is originating from the blood as we find 
elevated levels of EREG following CFA and SNI, which parallel EREG mRNA expression levels 
in TMD patients. 
 In summary, we find that clinically available small molecule EGFR inhibitors targeting the 
tyrosine kinase site of the EGFR receptor, including gefitinib and lapatinib, are effective analgesics 
in mice, for inflammatory and neuropathic pain. These drugs are routinely given to non-small-cell 
lung cancer patients (38, 39) to inhibit tumor growth, but have not been systematically studied for 
their role in pain management. Since we find that EREG is the primary endogenous activator of 
EGFR-related pain hypersensitivity, our data suggest that an effective treatment strategy may be 
the selective inhibition of EREG over other endogenous EGFR ligands. Directly targeting EREG 
may result in a reduced side-effect profile when compared with currently available EGFR-
inhibition strategies.  
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METHODS 
 
Study design  
Animals were randomized to drug condition using within-cage randomization, and all behavioral 
experiments were performed by an experimenter blinded to drug conditions. As we had no a priori 
expectation of effect sizes, power analyses were not used to calculate sample sizes. Instead, we 
adhered to standard practices in the field (38). In many cases, sample sizes were dictated by 
breeding success. Statistical outliers were defined via Studentized residuals >3, and excluded 
before analyses were run.  
 
Rodent subjects 
Most experiments were performed on naive, adult (7–12 weeks of age) outbred CD-1® (ICR:Crl) 
mice of both sexes, bred in-house (J.S.M. laboratory) from breeders obtained from Charles River 
(Boucherville, QC). Heterozygote breeding pairs for mutant mice containing a large deletion of 
the extracellular domain of the EGFR receptor (EGFRvIII/EGFR) were obtained from the 
laboratory of Dr. David Threadgill (North Carolina State University) on a C57BL/6 background. 
We only tested heterozygote EGFRvIII/EGFR mice because the homozygotes are neonatally 
lethal. Null mutant mice for 4E-BP1 (Eif4ebp-/-; C57BL/6 background) and p70 S6 kinase 1/2 
double knockout mice (Rps6kb1/Rps6kb2 -/-; mixed 129Sv x C57BL/6 background) and their 
associated wildtypes were generated and bred in one of our laboratories (N.S.). The latter mutants 
were kindly provided by Dr. G. Thomas (University of Cincinnati). Mice lacking the MMP-9 gene 
(Mmp9 -/-) were purchased from The Jackson Laboratory on an FVB/NJ background and 
compared to wildtype mice of that strain. No overt behavioral abnormalities were noted in any of 
the mutant mouse strains. All mice were housed with their same-sex littermates (two to four 
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animals per cage) in standard shoebox cages, maintained in a temperature-controlled (20 ± 1 °C) 
environment (14:10 h light/dark cycle), and fed (Harlan Teklad 8604) and watered ad libitum. 
Mice were assigned to experimental conditions in a randomized fashion within-cage. 
 All procedures were approved by the local animal care and use committees at McGill 
University and the University of Toronto Mississauga and were consistent with national 
guidelines. 
 
Behavioral assays 
Subjects were habituated to the testing environment for at least 15 min in every assay before testing 
commenced. Animals were randomized to drug condition, and all behavioral experiments were 
performed by an experimenter blinded to conditions.  
  Rotarod test: Drug effects on motor coordination were tested using an accelerating rotarod 
treadmill (Acceler Rota-Rod 7650, UgoBasile) for mice (40). Mice were placed on the rotarod, 
which accelerated from 4 to 40 rpm over a period of 5 min, and the time spent on the rotating drum 
was recorded for each mouse. On the test day, one pre-injection baseline trial (drug-free) was 
performed before the animals were treated with either saline, AG 1478 (100 mg/kg), gefitinib (300 
mg/kg) or lapatinib (300 mg/kg). Performance was indicated by the latency to fall from the rotarod 
at 15–60 min after injection. 
 Radiant heat paw-withdrawal test: Mice were placed on a 3/16th-inch thick glass floor within 
small Plexiglas cubicles (9 × 5 × 5 cm high), and a focused high-intensity projector lamp beam 
was shone from below onto the mid-plantar surface of the hind paw (41). The commercial device 
(IITC Model 336) was set to 20% active intensity. Latency to withdraw from the stimulus was 
measured to the nearest 0.1 s. Baseline measurements consisted of testing both hind paws twice 
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on three separate occasions separated by at least 30 min. Following drug injection, both hind paws 
were only tested once at the indicated time.  
 von Frey test: The up-down method of Dixon (42) was used. Mice were placed on a perforated 
metal floor (with 5-mm diameter holes placed 7 mm apart) within small Plexiglas cubicles as 
described above, and a set of eight calibrated von Frey fibers (Stoelting Touch Test Sensory 
Evaluator Kit #2 to #9; ranging from ≈0.015 g to ≈1.3 g of force) were applied to the plantar 
surface of the hind paw until the fibers bowed, and then held for 3 s. The threshold force required 
to elicit withdrawal of the paw (median 50% withdrawal) was determined twice on each hind paw 
(and averaged) for all baseline measurements, with sequential measurements separated by at least 
20 min. For experiments in which a drug was injected, one measurement per hind paw was taken 
at the indicated time point. 
 Formalin test: Formalin injection produces a biphasic response: an acute, nociceptive "early" 
phase and a tonic, inflammatory "late" phase, separated by a quiescent period in which there is no 
apparent pain behavior (41). Mice were placed on a tabletop within Plexiglas cylinders (30 cm 
high; 30 cm diameter) and allowed to habituate. Then, 20 μl of 5% formalin was injected 
subcutaneously into the plantar surface of the left hind paw using a 100-μl microsyringe with a 
30-gauge needle. Mice were then returned to the cylinders, and left undisturbed for 60 min, with 
behaviors recorded using digital video. Videos were later coded offline, where the first 10 s of 
every minute was monitored for the presence of licking/biting (positive sample) of the left hind 
paw for a total of 60 observations. The early phase was defined as the percentage of positive 
samples during the first 0–10 min post-injection of formalin; the late phase as the percentage of 
positive samples during the period 10–60 min post-injection. For the drug studies, EGFR, TRPV1, 
TRPA1 and mTOR inhibitors were injected 20 min before formalin, and TIMP-1 was injected 1 h 
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before formalin. EGFR ligands and NGF were injected immediately before formalin. 
 Carrageenan: Carrageenan (2%; 20 mg/ml; Sigma) was suspended by sonication in saline, and 
injected subcutaneously in a volume of 20 μl into the left plantar hind paw using a 100-μl 
microsyringe with a 30-gauge needle. Mice were tested for thermal sensitivity of both hind paws 
using the radiant heat paw withdrawal test as described above, before and 3 h post-carrageenan 
injection. All drugs were injected immediately following the test for carrageenan hypersensitivity 
at the 3 h time point, and post-drug measurements were taken at 20, 40 and 60 min. 
 Complete Freund’s adjuvant: Complete Freund’s adjuvant (CFA; 50%; Sigma) was injected 
subcutaneously in a volume of 20 μl into the left plantar hind paw using a 100-μl microsyringe 
with a 30-gauge needle. Mice were tested for mechanical sensitivity of both hind paws using the 
von Frey test as described above, before and 3 days post-CFA injection. All drugs were injected 
immediately following the 3 day post-CFA test, and post-drug measurements were taken at 20, 40, 
60 and 90 min. Percentage of maximal possible anti-allodynia (i.e., reversal of allodynia back to 
pre-injection baseline values at all post-drug time points) was calculated using the trapezoidal 
method. 
 Spared nerve and chronic constriction injury: Spared nerve injury (SNI) and chronic 
constriction injury (CCI), two experimental nerve injury procedures designed to produce 
neuropathic pain, were performed under isoflurane/oxygen anaesthesia as described previously 
(43, 44). Mice were tested for mechanical sensitivity before and after surgery using the von Frey 
test as described above, except that the "spared" sural region was targeted for SNI and the 
mid-plantar surface was targeted for CCI by applying the fibers to the hind paw. All drugs were 
injected immediately following the test for SNI- or CCI-induced mechanical allodynia 7 or 14 days 
following surgery, respectively, and post-drug measurements were taken at 20, 40, 60 and 90 min. 
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Percentage of maximal possible anti-allodynia (i.e., reversal of allodynia back to pre-surgery 
baseline values at all post-drug time points) was calculated using the trapezoidal method.  
 Capsaicin and mustard oil:  Mice were allowed to habituate to an observation chamber (see 
formalin test above) for 15 min. Mice then received a subcutaneous injection of capsaicin (2.5 g; 
Sigma) or mustard oil (5%; Sigma) into the plantar left hindpaw (20 l) and were digitally 
videotaped for 10 min. Video files were later scored for the total duration (s) of licking/biting of 
the injected paw. 
 
Drugs 
AG 1478, gefitinib, lapatinib, rapamycin, CCI 779 and wortmannin were purchased from LC 
Laboratories (Woburn, MA) and dissolved in 30% polyethylene glycol except wortmannin, which 
was dissolved in 10% DMSO. EREG, EGF, betacellulin, amphiregulin, TGF-, NGF, AMG 9810, 
K252a, PD 98059 and TIMP-1 were purchased from R&D Systems (Minneapolis, MN) and were 
dissolved in sterile saline, except K252a and PD 98059, which were dissolved in 20% DMSO. 
Capsaicin, Mustard Oil and HC 030031 were purchased from Sigma Aldrich (Mississauga, ON). 
4EGI-1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and dissolved in 20% 
DMSO. Morphine sulfate was obtained from Health Canada and dissolved in saline. Drugs were 
administered either intraperitoneally (10 ml/kg volume) or intrathecally (5 l volume) (45). 
 
Enzyme-linked immunosorbant assay 
Mice received no treatment, formalin injection, CFA injection, or SNI surgery, and were 
euthanized 60 min (formalin), 3 days (CFA), or 7 days (SNI) later. Trunk blood was collected into 
EDTA-coated Vacutainer tubes/heparinized syringes. Blood was centrifuged at 15,000 rpm for 15 
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min at 4 °C to isolate plasma from other blood components. Plasma was aliquoted into tubes, 
frozen with liquid nitrogen, and stored at -80 °C. Plasma samples were then thawed on ice and 
EREG measured in duplicate using an enzyme-linked immunosorbant assay (ELISA) kit from 
Abcam (Cambridge, UK) according to manufacturer’s instructions.  
 
Immunohistochemistry 
Naive mice were deeply anesthetized with sodium pentobarbital (60 mg/kg) and perfused 
transcardially through the left cardiac ventricle with 100 ml of perfusion buffer, followed by 250 
ml of 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB), pH 7.4, at room temperature 
for 15 min. Subsequently, the spinal column was removed and post-fixed in the same fixative for 
24 h at 4 °C. Spinal cord lumbar segments L3 and L4, and DRGs at the same levels were extracted 
and cryoprotected with 30% sucrose in 0.1 M PB. Tissue was embedded in an optimum cutting 
temperature medium (Tissue Tek OCT; Sakura), and 16-μm and 50-μm transverse DRG and spinal 
cord sections, respectively, were cut at -20 °C on a Leica CM3050 S cryostat. DRG sections were 
placed directly on gelatin-subbed slides and spinal cord sections were collected as free-floating 
sections in phosphate-buffered saline (PBS). The staining protocols for slides and free-floating 
tissue were similar. Sections were rinsed three times with PBS, with 0.2% Triton X-100 (PBS-T) 
for 10 min, and pre-incubated with 10% normal goat serum (NGS) for 1 h. To assess the 
colocalization between EGFR and markers of primary afferent neuronal populations, sections were 
incubated overnight at 4 °C in 5% NGS with either: 1) anti-EGFR raised in rabbit (1:50, Santa 
Cruz, #SC-03, Lot F1512) or 2) anti-EGFR and anti-NeuN raised in mouse (1:5000, Millipore, 
#MAB377, Lot 2062313). To assess the specificity of the EGFR antibody, the diluted antibody 
(1:50) was pre-incubated with the EGFR blocking peptide (1:5, Santa Cruz, #SC-03p, Lot E2109) 
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overnight at 4 °C in PBS before adding it to the tissue. The next day, tissue was washed three times 
with PBS-T for 10 min, incubated in Alexa 488 anti-rabbit (1:800, Invitrogen, #A11034, Lot 
870976), Alexa 594 anti-guinea pig (1:800, Invitrogen, #A11076, Lot 714263), or Alexa 568 anti-
mouse goat secondary antibodies (1:800, Invitrogen, #A11031, Lot 822389) in the dark for 2 h, 
and washed two times with PBS-T and one time with PBS. Free-floating sections were mounted 
on slides. All slides were coverslipped with Aqua-Poly/Mount (Polysciences). Sections were 
examined using a Zeiss LSM 510 confocal scanning laser microscope, equipped with Argon and 
Helium-Neon lasers using a multi-track approach.  
 
Western blots 
Tissue extracts for Western blotting were prepared in ice-cold homogenization buffer containing 
(in mM): 50 Tris-HCl, pH 7.4; 150 NaCl; 1 EDTA; 1% Triton X-100; 5 NaF; 1.5 Na3VO4 and 
protease inhibitor cocktail (complete, EDTA-free, Roche Applied Science, Indianapolis, IN). For 
measuring MMP-9, DRGs were removed from animals that were perfused transcardially with PBS. 
Following centrifugation at 12,000 × g for 10 min at 4 °C, the supernatant protein concentration 
was measured and equal protein quantities were boiled for 5 min in sample buffer and separated 
by SDS-PAGE. Following electrophoresis, proteins were transferred to 0.2 mm nitrocellulose 
membranes. Membranes were blocked in 5% dry milk powder in Tris-buffered saline containing 
0.1% Tween-20 (TBS-T) for 1 h prior to overnight incubation with primary antibody. The 
membranes were then washed, incubated for 1 h with HRP-conjugated secondary antibody, 
washed again, treated with Enhanced Chemiluminescence reagent (Perkin Elmer) and exposed to 
autoradiography films (Denville Scientific Inc.). All signals were obtained in the linear range for 
each antibody, and densitometric analyses were performed with Image J (National Institutes of 
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Health, Bethesda, MD). Each phosphoprotein was normalized to the expression of the 
corresponding total protein. The antibodies and dilutions for the Western blots used in these studies 
are as follows: 4E-BP1 (1:1000, Cat. #9644, Cell Signaling Technology), p-4E-BP1 (Thr37/46) 
(1:1000, Cat. #2855, Cell Signaling Technology), AKT (1:1000, Cat. #4685, Cell Signaling 
Technology), p-AKT (Ser473) (1:1000, Cat#9271, Cell Signaling Technology), EGFR (1:1000, 
Cat. #sc-03, Santa Cruz Biotechnology), p-EGFR (1:1000, Cat. #3777, Cell Signaling 
Technology), MMP-9 (1:1000, Cat. #AB19016, Chemicon), S6 (1:1000, Cat. #sc-74459, Santa 
Cruz Biotechnology), p-S6 (Ser240/244) (1:1000, Cat. #2215, Cell Signaling Technology), and 
β-actin (1:5000, Cat. #A5441, Sigma). 
 
Calcium imaging 
Mouse lumbar DRG neurons (L3–L5; at least n=4 mice per condition) were harvested and cultured 
as previously described(46). Briefly, DRGs were isolated, transferred into Hank’s Balanced Salt 
Solution (HBSS) and enzyme-digested by incubation with papain and collagenase type II 
(Worthington Biochemical Corp.). Dissociated neurons were plated on glass coverslips coated 
with poly-d-lysine and laminin and maintained at 37 °C at 5% CO2/95% air in F12 media (Life 
Technologies) with 10% FBS. After 2–6 h, dissociated neurons on coverslips were loaded with 1 
µM of the cell permeable calcium sensitive dye, Fura-2, AM (Life Technologies) for 30 min, and 
washed with HBSS before use. Coverslips were placed in a chamber containing HBSS at room 
temperature (20–22 °C) for recordings under following conditions: baseline (1-min recording, no 
solution); treated either with vehicle (DPBS) or EREG (200 ng/ml) for 10 min and then stimulated 
either with capsaicin (1 µM) or mustard oil (100 nM) for 30 s. Seventy-five mM KCl was added 
at the end of recordings, and only neurons with a positive KCl response were included in the 
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analysis. In the repeated capsaicin-pulse experiments, after baseline recording, 25 mM KCl was 
applied for 15 s followed by capsaicin (500 nM in HBSS) application for 15 s every 4 min as 
previously described (47). HBSS (vehicle) or EREG (200 ng/ml) was applied for 6 min after the 
fourth, fifth or sixth application of capsaicin, when the response had largely stabilized. After the 
incubation, three more pulses of capsaicin were applied and the ratio of the Ca2+ increases before 
and after exposure to EREG or HBSS was calculated as an index of enhancement. EREG caused 
sensitization in approximately 29% of capsaicin-responsive neurons (58 out of 197 capsaicin-
stimulated cells). Fluorescence was detected by a Zeiss Observer Ratio Z1 microscope at 340 nm 
and 380 nm excitation wavelengths and analyzed with ZEN Black software (Zeiss). Cells were 
considered responsive to a drug infusion if the 340/380 ratio increase was ≥0.2 from baseline. 
Percentage of responsive neurons was determined for each coverslip and the average percentage 
values were compared statistically. 
  
Quantitative real-time PCR 
DRGs (L3–L4) were isolated and subjected to RNA extraction using TRIzol (Invitrogen, 
Burlington, ON). Reverse transcription was performed using a SuperScript III Reverse-
Transcriptase Kit and Random Hexamers (Invitrogen) according to the manufacturer’s 
instructions. qRT-PCRs were carried out in a CFX96-PCR system using iQ Sybr Green Supermix 
RT (Bio-Rad, Mississauga, ON) according to the manufacturer’s instructions. The following 
primers were used: Mmp9 (forward) GATCCCCAGAGCGTCATTC; Mmp9 (reverse) 
CCACCTTGTTCACCTCATTTTG, Gapdh (forward) TCCATGACAACTTTGGCATTG; 
Gapdh (reverse) CAGTCTTCTGGGTGGCAGTGA. Analyses were carried out in triplicate and 
the Mmp9 signal was normalized to Gapdh. 
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Polysomal profile analysis 
Lumbar DRGs (L3–L5; pooled from at least n=10 mice per condition) were isolated and placed in 
ice-cold HEPES-KOH HBSS (Hank's Balanced Salt Solution, pH 7.4) containing 100 g/ml 
cyclohexamide. HBSS was replaced with the ice-cold hypotonic lysis buffer(48) containing 
protease (complete EDTA-free, Roche Products) and RNase inhibitors (Rnasin, Promega, 
Madison, WI), and the tissue was subjected to brief homogenization using a glass homogenizer. 
The homogenated material was spun at 18,000 g for 2 min at 4 °C, and the supernatant loaded on 
a 10-50% w/w sucrose gradient in 20 mM HEPES-KOH, pH 7.6, 100 mM KCl and 5 mM MgCl2, 
and centrifuged at 35,000 g for 2.5 h at 4 °C in an Optima L-80 XP ultracentrifuge (Beckman 
Coulter) using an SW40Ti rotor. Polysome analysis was performed by measuring the optical 
density (OD) at 254 nm using an ISCO fractionators (Teledyne ISCO; Lincoln, NE), as described 
previously (48). qRT-PCR analysis was performed as previously described (49). Sucrose gradient 
fractions were subjected to RNA extraction using TRIzol (Invitrogen). Reverse transcription was 
performed using a SuperScript III Reverse-Transcriptase Kit (Invitrogen) and Random Hexamers 
(Invitrogen) according to the manufacturer’s instructions. qRT-PCRs were carried out in a CFX96 
(Bio-Rad) RT-PCR system using iQ Sybr Green Supermix (Bio-Rad) according to the 
manufacturer’s instructions using the following primers (Mmp9 forward: 
GATCCCCAGAGCGTCATTC; Mmp9 reverse: CCACCTTGTTCACCTCATTTTG). For all 
experiments n=4 (technical replicates); results are presented in arbitrary units as relative amounts 
using serial dilutions of DRG or spinal RNA as qRT-PCR concentration standards. 
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Drosophila experiments 
Flies were reared on cornmeal-molasses-yeast agar at 25 C, 70% humidity, on a 12:12-h light/dark 
cycle. ppk-Gal4, Egfr mutants Egfrf24 and Egfrtsla lines were obtained from the Bloomington 
Drosophila Stock Centre (BDSC; Bloomington, IL). Wildtype w1118 and Egfr short hairpin 
RNA-interference (RNAi) (transformant ID 107130) flies were obtained from the VDRC (Vienna, 
Austria).  
 Larval nociceptive behavior was analysed according to previously described methods (24).  
Third instar larvae were transferred to a 100 mm petri dish containing a thin film of distilled water 
and allowed a 10-min rest period. After this time, they were touched on abdominal segments A4–
A6 with a heat probe consisting of a sharpened soldering iron with the tip heated to 46 °C. The 
response time was recorded as the time elapsed between application of the heat probe and the 
elicitation of the characteristic nociceptive withdrawal response, a 360° rolling motion about the 
lateral axis. Both male and female flies (n=60/genotype) were tested on at least three different 
days. 
 
Human subjects and phenotyping 
Genotype and phenotype data from the OPPERA case-control study are available at the Database 
of Genotypes and Phenotypes (dbGaP), accession number: phs000762.v1.p1. The OPPERA cohort 
was recruited and phenotyped as detailed previously (50, 51), and described briefly here. 
Volunteers were recruited at four U.S. study sites. Cases (n=127) had examiner-verified TMD at 
enrollment; controls (n=731) were individuals who reported no significant history of TMD 
symptoms. Classification of TMD was based on the Research Diagnostic Criteria (RDC) for 
Temporomandibular Disorder (52). To increase genetic homogeneity of the cohorts, only 
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Caucasian subjects were analyzed in this study; results from the full cohort were extremely similar. 
An additional subgroup of “supercontrols” (n=231 Caucasians) was classified post hoc as 
TMD-free controls who experienced no tenderness during palpation of 8 masticatory muscles and 
two temporomandibular joints. Their genotypes were contrasted with 129 Caucasian TMD cases.  
 The TMD case-control cohort (26) included 200 TMD cases and 198 controls, using similar 
recruitment protocols and diagnostic criteria as OPPERA with the exception that enrollment was 
open to non-Hispanic Caucasian females age 18-45, and cases were recruited through a tertiary 
care pain clinic rather than from the general population.  
 The pre-OPPERA cohort (27) included n=186 initially pain-free Caucasian females age 18–
34, of which 15 developed RDC-verified TMD over the course of the three year follow-up. 
Measures of sensitivity to multitude of pain-evoking stimuli have been also collected in all three 
cohorts (26, 27, 50, 51). 
 Only subjects who gave written, informed consent and provided a sample of blood for 
genotyping were included in the present analyses, and all study protocols were approved by the 
respective institutional review boards. 
 
Genetic association 
Genetic analysis of the OPPERA cohort was described previously (53). Genotyping was performed 
on DNA extracted from whole blood, using the Pain Research Panel (Algynomics Inc., Chapel 
Hill, NC). The Pain Research Panel is a microarray platform that assesses 3,295 SNP markers 
representing 358 genes of potential relevance to pain, inflammation, and/or mood and affect, as 
well as 160 ancestry informative markers used to adjust for population stratification. Duplicate 
study samples and HapMap reference DNA were genotyped to confirm accuracy and reliability of 
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genotyping, and quality filters were imposed for call rate >95%, reliability >99%, minor allele 
frequency >1%, and adherence to Hardy-Weinberg equilibrium. The overall call rate was 99.7%, 
with 2,924 SNPs passing quality filters. Genotyping of the pre-OPPERA cohort was performed 
separately on the Pain Research Panel using DNA from whole blood after amplification. 
 PLINK v.1.07 (Broad Institute, Cambridge, MA) software (54) was used to perform case-
control association tests by logistic regression, assuming a co-dominant inheritance model. All 
tests on the OPPERA cohort controlled for recruitment site, and tests which included non-
Caucasians also adjusted for race using the first two eigenvectors of a principal components 
analysis (PCA) on the genotype matrix (55).  
 After initial association tests performed in OPPERA identified EREG and EGFR, five SNPs 
from EREG and 25 SNPs from EGFR were extracted from the full SNP panel. Haplotype blocks 
were identified in each gene using Haploview v.4.2 (56), and tag SNPs were selected to cover 
haplotypic variation in EREG (rs2367707, rs7687621, rs1542466) and EGFR (5’ region: rs759171, 
rs4947963; 3’ region: rs1140475, rs2740762, rs845552). Haplotype testing was performed in the 
R statistical environment using logistic regression. Omnibus tests were used to detect differences 
in TMD odds between any major haplotype group, and post hoc tests were performed contrasting 
individual haplotypes against all others in order to characterize their effects. Combined p-values 
for haplotype analysis were calculated using the optimally weighted Z-test (57). 
 To explore cellular mechanisms underlying the associations, we applied bioinformatic 
pathway analysis (based on Pathway Studio, Elsevier) to identify signaling networks implicated 
by the association results in the discovery cohort. The multiple-testing-adjusted significance 
threshold was determined to be 0.002 for the 5% level, as determined through permutation (58). 
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Human mRNA studies 
Leukocytes were obtained from 6 ml heparinized venous blood from human subjects. Briefly, 
whole blood was diluted in endotoxin-free RPMI-1640 medium and centrifuged through 
Ficoll/Histopaque 1077 (Sigma Chemical Co., St Louis, MO), and the buffy coat cells were 
washed five times with sterile isotonic saline. Total RNA was isolated with Trisol Reagent (Life 
Technologies, Grand Island, NY) and RT-PCR was performed analyzed with the SABioscience 
Custom PCR array system (Valencia, CA). The cDNAs from all participants were normalized to 
GAPDH through dilution to the concentration at which GAPDH gave an equal signal in RT-PCR 
reactions. 
 Human cDNA amplified from study participants with the major EREG haplotype was cloned 
into pCDNA3 vectors under a CMV-promoter to generate a wildtype expression EREG plasmid 
(gift from Dr. Oskar Laur, Emory University, Atlanta GA). Briefly, an expression plasmid with 
the minor allele at rs2367707 was generated by site-directed mutagenesis. Expression plasmids 
were transiently transfected into HEK293 cells using Lipofectamine 2000 (Life Technologies) in 
accordance with manufacture’s recommendations. The time course of mRNA degradation was 
measured after actinomycin D (actD; Sigma) treatment. Thirty-six hours after transfection of 
EREG plasmids, cells were treated with actD (10 μg/ml) and collected at 0, 2, 4, or 6 h post 
treatment. Total RNA was isolated after each time point using Trizol reagent (Life Technologies). 
The isolated RNA was treated with RNase free-DNase I (Promega) and reverse transcribed using 
a SuperScript III Reverse-Transcriptase Kit (Invitrogen) and Random Hexamers (Invitrogen) 
according to the manufacturer’s instructions. qRT-PCRs were carried out in a CFX96 (Bio-Rad) 
RT-PCR system using iQ Sybr Green Supermix (Bio-Rad) according to the manufacturer’s 
instructions. cDNAs of EREG and the housekeeping gene, GAPDH, were amplified using forward 
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and reverse PCR primers (GGCTATTGTTTGCATGGACAG and 
CACGGTCAAAGCCACATATTC, for EREG; and CTTTGGTATCGTGGAAGGACTC and 
GTAGAGGCAGGGATGATGTTC, for GAPDH). Two independent experiments were conducted 
in triplicate. Data were normalized to GAPDH. 
 
Statistical analyses 
Data were analyzed by two-tailed Student's t-test (unless otherwise indicated), one-way or 
two-way ANOVA (or Kruskal-Wallis ANOVA by ranks), followed where appropriate by Tukey's 
HSD posthoc test or Dunnett's case-comparison posthoc test. A P value less than 0.05 was 
considered significant. Four data points were excluded based on their identification as statistical 
outliers (Studentized residuals >3). AD50s and associated 95% confidence intervals were 
calculated using the FlashCalc 40.1® macro (M.H. Ossipov, University of Arizona). As we had no 
a priori expectation of effect sizes, power analyses were not used to calculate sample sizes. Instead, 
we adhered to standard practices in the field (59). In many cases, sample sizes were dictated by 
breeding success. 
 
Study approval 
Mice were maintained in the animal facilities of McGill University and the University of Toronto 
Mississauga. All mouse experiments were approved and performed in accordance with relevant 
local animal care and use committees according to the Canadian Council on Animal Care (CCAC) 
guidelines. The OPPERA study was reviewed and approved by Institutional Review Boards at 
each of the 4 study sites and at the data coordinating center: University at Buffalo (Buffalo, NY); 
University of Maryland (Baltimore, MD); University of North Carolina at Chapel Hill (Chapel 
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Hill, NC); University of Florida (Gainesville, FL); and the Battelle Memorial Institute (Durham, 
NC). All participants verbally agreed to a screening interview done by telephone and they provided 
informed, signed consent for all other study procedures. 
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FIGURE LEGENDS 
 
Figure 1. EGFR antagonists produce analgesia and EREG produces hyperalgesia in the mouse. 
(A) No sedation or ataxia (two-way ANOVA, drug x repeated measures: F12,80=0.5, p=0.88) 
produced by high doses of EGFR antagonists. Symbols represent mean ± SEM latency (s) to fall 
off rotarod at each time point; n=6–8/drug. (B) No effect of EGFR antagonists on acute thermal 
pain measured using the radiant heat paw-withdrawal test (two-way ANOVA, drug x repeated 
measures: F3,19=2.3, p=0.10). Bars represent mean ± SEM latency (s) to withdraw from a noxious 
thermal stimulus before (baseline) and 30 min after (post-drug) injection; n=5–6/drug. (C) No 
effect of EGFR antagonists on acute mechanical sensation using the von Frey test (two-way 
ANOVA, drug x repeated measures: F3,19=0.3, p=0.80). Bars represent mean ± SEM hind paw 
withdrawal threshold (g) before (baseline) and 30 min after (post-drug) injection; n=5–6/drug. (D) 
EGFR antagonists produce analgesia on the formalin test in both the early (0–10 min; one-way 
ANOVA, F3,29=7.2, p=0.001) and late (10–60 min; one-way ANOVA, F3,29=15.9, p<0.001) 
phases. Bars represent mean ± SEM percentage of samples featuring licking/biting behavior; n=7–
9/drug. (E) Dose-dependent analgesia from EGFR antagonists and morphine on the late-phase 
formalin test; symbols represent mean ± SEM percentage of samples featuring licking/biting 
behavior; n=6–8/drug/dose. See Supplemental Table 1 for half-maximal analgesic doses and 95% 
confidence intervals. (F) EGFR antagonists reverse thermal hypersensitivity induced by 
carrageenan (two-way ANOVA, drug x repeated measures: F9,57=2.8, p=0.01). Symbols represent 
mean ± SEM latency (s) to withdraw from a noxious thermal stimulus before carrageenan 
(Pre-BL), 3 h after carrageenan (0), and 20–60 min post-drug; n=5–6/drug. (G) EGFR antagonists 
dose-dependently reverse mechanical allodynia induced by complete Freund’s adjuvant (CFA; 3 
days post-injection). Symbols represent mean ± SEM percentage of maximum possible 
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anti-allodynia (i.e., reversal back to baseline withdrawal thresholds at all post-drug time points; 
see Methods); n=5–6/drug/dose. (H) EGFR antagonists dose-dependently reverse mechanical 
allodynia induced by spared nerve injury (SNI; 7 days post-surgery). Symbols as in G; n=5–
6/drug/dose. See Supplemental Table 2 for half-maximal analgesic doses and 95% confidence 
intervals relevant to graphs G, H. (I) AG 1478 reverses mechanical allodynia induced by chronic 
constriction injury (CCI; 14 days post-surgery); n=6/drug (two-way ANOVA, drug x repeated 
measures: F4,40=2.6, p=0.02). For all panels, *p<0.05, **p<0.01, ***p<0.001 compared to vehicle 
(0) group by Dunnett’s case-comparison posthoc test.  
 
Figure 2. Spinally administered EREG, but not other EGFR ligands, produces 
hypersensitivity. (A) Significant and dose-dependent hypersensitivity from EREG (two-way 
ANOVA, F3,26=6.8, p=0.002), but not betacellulin, amphiregulin, EGF or TGF- (all p’s>0.50) in 
the late phase (10–60 min) of the formalin test.  Symbols represent mean ± SEM percentage of 
samples featuring licking/biting behavior; n=6–8/drug/dose. EREG enhancement of formalin-
induced licking was equivalent to that of nerve growth factor (NGF); two-way ANOVA, 
F3,22=10.9, p<0.001. (B) EREG (10 ng, i.t.) increases nocifensive behavior when co-administered 
with intraplantar injections of the TRPV1 agonist capsaicin (two-tailed t-test, t10=3.4, p=0.01) but 
not the TRPA1 agonist mustard oil (two-tailed t-test, t13=0.34, p=0.70). Bars represent mean ± 
SEM duration of licking behavior (s) over 10 min post-injection; n=6-8/algogen/drug.  (C) The 
TRPV1 antagonist, AMG 9810 (30 mg/kg, i.p.), but not the TRPA1 antagonist, HC-030031 (30 
mg/kg, i.p.) blocks EREG-induced hyperalgesia on the formalin test (two-way ANOVA, drug x 
antagonist interaction: F2,38=7.2, p=0.002). Bars as in graph A; n=7-8/group.  (D) EREG (10 ng) 
increases thermal sensitivity by itself (two-tailed paired t-test, t10=2.6, p=0.03). Bars represent 
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mean ± SEM latency (s) to withdraw from a noxious thermal stimulus before (baseline) and 30 
min after (post-drug) injection; n=6/drug. (E) EREG (10 ng) increases mechanical sensitivity by 
itself (two-tailed paired t-test, t10=2.2, p=0.05). Bars represent mean ± SEM hind paw withdrawal 
threshold (g) before (baseline) and 30 min after (post-drug) injection; n=6/drug. (F) EGFR 
mutants have higher baseline pain sensitivity to formalin than wildtypes (vehicle groups), but no 
longer respond to EREG (10 ng, i.t.). Bars as in graph E; n=7–8/genotype/drug. For all panels, 
*p<0.05, **p<0.01, ***p<0.001 compared to vehicle (0) by Dunnett’s case-comparison posthoc 
test or t-test as indicted. ●●p<0.01 compared to other genotype (in F) by Dunnett’s case-comparison 
posthoc test. 
 
Figure 3. Genetic association of EREG and EGFR with TMD pain.  Genetic association of 
EREG (A) and EGFR (B) SNPs with chronic TMD pain in OPPERA Cases vs. Supercontrols 
("SC"), OPPERA Cases vs. Controls ("all"), TMD Case-Control cohort, and pre-OPPERA cohorts 
(see Materials and Methods). Manhattan plots and corresponding gene loci are shown where 
position of tested SNPs is given relative to gene structure. Non-synonymous (red), synonymous 
(green), promoter region (grey) and 3’ intragenic region (blue) SNPs are indicated. The pattern of 
association within the EREG gene locus was identical in all cohorts. The pattern of association for 
EGFR gene locus revealed some differences between cohorts; however, the 5’ and 3’ ends of the 
gene consistently showed association with elevated TMD risk. The EGFR SNPs showing 
association in independent SNP tests (marked in bold) were used for haplotype analysis (see 
Supplementary Table 5). (C) Forest plot depicting odds ratios (OR; with 95% confidence intervals) 
for minor allele T of rs1563826 in four human chronic pain cohorts. (D) Association of EREG 
mRNA level with EREG rs1563826 in the TMD case-control cohort measured by quantitative 
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RT-PCR. Bars represent mean ± SEM EREG expression in leukocytes expressed in arbitrary units 
relative to GAPDH (see Materials and Methods). One-way ANOVA revealed a significant 
difference among genotypes; F2,247=3.7, p=0.03. *p<0.05; the A/A versus T/T comparison was 
p=0.053, likely due to the small number of T/T homozygotes. (E) Following actinomycin D (actD) 
treatment, the rate of mRNA degradation was significantly lower for cells expressing wildtype 
(WT; G allele) EREG mRNA compared to those the minor A allele of rs2367707 (two-tailed paired 
t-test, t4=2.8, p=0.05). Symbols represent mean ± SEM percentage mRNA expression compared 
to time 0; n=3/genotype. 
 
Figure 4. EREG and EGFR are upregulated in chronic pain states, and EREG increases 
activation of medium-small DRG sensory neurons. (A) EREG in the blood is upregulated by 
CFA and SNI, but not formalin (F3,38=10.0, p<0.001) as measured by ELISA. Bars represent mean 
± SEM protein levels (pg/ml); n=9–10 biological replicates/group. One-way ANOVA followed by 
Dunnett’s case-comparison post-hoc test, *p<0.05, ***p<0.001 compared to control group. (B) 
EGFR (green) is abundantly found in all DRG sensory neurons. Scale bar = 50 m. (C) The cellular 
distribution of EGFR is equal among different cell sizes that exhibit either high or low EGFR 
staining. (D) Top: Representative Western blots showing phosphorylated (p-)EGFR and -actin 
in the DRG before (BL) (left band) and 3 days (3d) or 7 days (7d) after CFA or SNI, respectively 
(right band). Bottom: Quantification of Western blot data (n=5 biological replicates/condition), 
after normalization to -actin and compared to baseline values. *p<0.05 compared to 1.0 by one-
tailed t-test (CFA: t4=2.5, p=0.03; SNI: t4=3.3, p=0.02. (E) Fluorescence microscopic images 
(Fura-2 340/380-nm ratio) of DRG neurons from naïve mice at baseline (top row, 1-min 
recording); treated either with vehicle (Veh; DPBS) or EREG (200 ng/ml) for 10 min (second row) 
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and then stimulated either with the TRPV1 agonist, capsaicin (Cap, 1 µM) or the TRPA1 agonist, 
mustard oil (MO, 100 nM) for 30 s (third row). KCl (75 mM) was added at the end of recordings 
and only neurons with a positive KCl response were included in the analysis. Scale bars = 50 µm.  
(F) The 340/380-nm ratio increase from the baseline before application of Cap or MO to the peak 
maximum after application (Δ ratio). Bars represent mean ± SD of delta ratio of responsive neurons 
treated either with Vehicle+Cap, EREG+Cap, Veh+MO, or EREG+MO; n=34-36/group. Two-
way ANOVA, algogen x vehicle/EREG:  F3,136 = 16.2, p<0.001). Unpaired Student’s t-test, 
***p<0.001. (G) Representative calcium traces of neurons responsive to multiple capsaicin (500 
nM, 15 sec for every 4 min) pulses and treated either with vehicle (HBSS, left figure) or EREG 
(200 ng/ml, right figure) for 6 min before three challenging pulses of capsaicin were applied. The 
ratio of Ca2+ peak heights (b/a) before and after exposure to EREG or vehicle was calculated as a 
measure of signal enhancement. (H) EREG but not vehicle enhanced the TRPV1 currents of 
capsaicin challenge pulses.  Data presented as mean ± SEM, n=45-58/group, from a total of 9/13 
experiments for vehicle/EREG. Unpaired Student’s t-test, ***p<0.001.      
 
Figure 5. EREG/EGFR increases pain through a PI3K/AKTmTOR4E-BP1eIF4F 
complexMMP-9 signaling pathway. (A) The signaling pathway investigated, with major 
proteins indicated in black and blocking drugs or mutants shown in red. (B) Treatment with 
wortmannin (5 g, i.t.) blocks EREG-induced increases in late-phase formalin-induced pain 
behavior (drug x drug: F1,23 = 4.7, p=0.04). (C) Low doses of rapamycin (5 mg/kg) and CCI 779 
(1 mg/kg) block EREG effects without affecting formalin-induced pain per se (rapamycin, drug x 
drug: F1,27 = 3.6, p=0.04; CCI 779 drug x drug: F1,28 = 4.2, p=0.03); higher doses (10 mg/kg) are 
analgesic (main effects: rapamycin, F1,28 = 22.9, p<0.001; CCI 779, F1,28 = 30.2, p<0.001). (D) No 
effect on EREG increases in formalin-induced pain behavior in SGK1/2 (Rps6kb1/Rps6kb2) 
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double null mutant mice (Rps6kb1/2-/-; main effect of drug: F1,18 = 25.8, p<0.001). (E) Lack of 
EREG effects in 4E-BP1 (Eif4ebp1-/-) null mutant mice (genotype x drug: F1,33 = 7.1, p=0.01). (F) 
Treatment with 4EGI-1 (25 g, i.t.) blocks EREG effects (drug x drug: F1,20 = 7.6, p=0.01). (G) 
Treatment with TIMP-1 (4 pmol, i.t.) blocks EREG effects (drug x drug: F1,30 = 5.6, p=0.02). (H) 
Lack of EREG effects in MMP-9 null mutants (Mmp9-/-; genotype x drug: F1,20 = 16.1, p=0.001). 
In all experiments, EREG was injected at 10 ng, i.t. Bars in all graphs represent mean ± SEM 
percentage of samples featuring licking/biting behavior; n=6–8/drug/dose and n=6–
12/drug/genotype (dependent on breeding success). Two-way ANOVA for all panels followed by 
t-test compared to EREG vehicle, *p<0.05, **p<0.01, ***p<0.001; compared to wortmannin, 
rapamycin, CCI 779, 4EGI-1 or TIMP-1 vehicle, or +/+ genotype •p<0.05, ••p<0.01, •••p<0.001; 
compared to rapamycin/CCI 779 vehicle °p<0.05. 
 
Figure 6. EREG and formalin induce phosphorylation of AKT and 4EBP-1 and increase the 
expression of MMP-9 in lumbar DRG tissue. EREG (10 ng, i.t.) or 5% formalin (20 l, 
intraplantar) was injected and lumbar DRG tissue harvested 40 min later. Rapamycin was injected 
20 min before EREG or formalin to mimic behavioral experiment parameters. (A) Representative 
Western blots showing the phosphorylated (p-) and total protein abundance for AKT, 4E-BP1 and 
S6. The total amount of MMP-9 is also presented. Quantification (phosphorylated/total) for the 
percent-fold increase (compared to the control condition) in phosphorylated AKT, 4E-BP1, and 
S6 is presented in panels B–D along with the quantification for total MMP-9 (panel E), bars 
represent mean ± SEM for relative change in protein expression. (B) EREG significantly increases 
the phosphorylation of AKT in DRG tissue. (C) Both formalin and EREG increase the 
phosphorylation of 4E-BP-1, and the increases are blocked by rapamycin. (D) The phosphorylation 
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of S6 is significantly elevated relative to control tissue by EREG treatment, an increase blocked 
by rapamycin. (E) Formalin and EREG significantly increase MMP-9 expression and these 
increases are blocked by rapamycin. Sample sizes in all groups are n=4–6. One-way ANOVA for 
all panels followed by Dunnett’s case-comparison post-hoc test, *p<0.05, **p<0.01, ***p<0.001 
compared to control tissue. †p<0.05 decrease compared to EREG or formalin alone group. p<0.05 
increase compared to EREG or formalin alone group.  
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SUPPLEMENTARY MATERIALS 
 
 
SUPPLEMENTAL FIGURE 1. The effect of EGFR and Trk blockers on EREG-induced 
hyperalgesia on the formalin test.  
 
SUPPLEMENTAL FIGURE 2. Egfr knockdown alters nociceptive responses to noxious thermal 
stimuli in Drosophila. 
 
SUPPLEMENTAL FIGURE 3. Human genetic association findings. 
 
SUPPLEMENTAL FIGURE 4. EGFR spinal cord immunohistochemistry. 
 
SUPPLEMENTAL FIGURE 5. The effect of EREG on calcium responses and measures of 
excitability in DRG neurons. 
 
SUPPLEMENTAL FIGURE 6. Inhibition of the ERK pathway produces analgesia, but does not 
block EREG hypersensitivity. 
 
SUPPLEMENTAL FIGURE 7. MMP-9 inhibition blocks EREG hypersensitivity, and Mmp9 
null mutant mice are less sensitive to the analgesic properties of gefitinib on the formalin test.  
 
SUPPLEMENTAL FIGURE 8. EREG stimulates MMP-9 mRNA translation in an mTOR-
dependent manner. 
 
SUPPLEMENTAL TABLE 1. Half-maximal analgesic doses (AD50s) and 95% confidence 
intervals (95% CI) for EGFR inhibitor reversal of pain behavior on the late-phase of the formalin 
test. 
 
SUPPLEMENTAL TABLE 2. Half-maximal analgesic doses (AD50s) and 95% confidence 
intervals (95% CI) for EGFR inhibitor reversal of mechanical hypersensitivity after CFA (day 3 
post-injection) and SNI (day 7 post-surgery).  
 
SUPPLEMENTAL TABLE 3. Demographic characteristics of four human pain cohorts.  
 
SUPPLEMENTAL TABLE 4. Top-ranking p-values of cellular pathways associated with TMD 
in discovery cohort OPPERA cases vs. "supercontrols".  
 
SUPPLEMENTAL TABLE 5. Association analyses for EGFR haplotypes.  
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